Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...
For 2024, we now anticipate restructuring expenses to be approximately $450 million as we continue to optimize our cost ...
Time will tell if the "Trump Administration" as Ryan calls it will resort to using technology mostly promoted by left-leaning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback